Entrectinib companion diagnostic - Foundation Medicine
Alternative Names: Entrectinib - FoundationOne® CDx Cancer Genomic Profile; F1L CDx; Rozlytrek companion diagnosticLatest Information Update: 18 Sep 2024
Price :
$50 *
At a glance
- Originator Foundation Medicine
- Developer Chugai Pharmaceutical; Foundation Medicine
- Class Antineoplastics; Benzamides; Diagnostic agents; Fluorinated hydrocarbons; Indazoles; Piperazines; Pyrans; Small molecules; Tumour-agnostic therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer; Solid tumours
Most Recent Events
- 18 Sep 2024 Launched for Non-small cell lung cancer (Diagnosis) in Japan (unspecified route) prior to September 2024 (Foundation Medicine website, September 2024)
- 18 Sep 2024 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route) prior to September 2024 (Foundation Medicine website, September 2024)
- 18 Sep 2024 Launched for Solid tumours (Diagnosis) in Japan (unspecified route) prior to September 2024 (Foundation Medicine website, September 2024)